Core B is responsible for confirming all cancer reports and all deaths in the Nurses'Health Study cohort.
The specific aims for this core are as follows: 1) To document and confirm reports of incident cancer as collected from the questionnaires, telephone interviews, and death records. 2) To identify all deaths among cohort participants and to ascertain the cause of death. 3) To provide standardized data files of cancer diagnoses and all deaths for epidemiologic analyses. Under the direction of Meir Stampfer, MD, DrPh, Core B obtains medical records and other relevant information to confirm cancer diagnoses and cohort deaths. The trust that has evolved over the past thirty-two years between the NHS investigators and cohort participants has led to an extremely high degree of cooperation in securing permission to review medical records, and from the families in ascertaining the details of the cause of death. Medical records are reviewed by physicians according to uniform standardized criteria to confirm the cancer diagnoses and obtain details of the histopathology, including tumor site, stage, and grade. We learn of most deaths through the questionnaire mailings and we search the National Death Index for questionnaire nonrespondents. State tumor registries are also utilized to confirm cancer diagnoses and deaths. Custom-designed computer software has been developed to track the progress from the initial report of a diagnosis or death to the final confirmation. The software also automatically generates letters to participants and medical institutions for requesting medical records and additional Information. At the end of every biennial follow-up cycle, standardized files are generated for specific cancer diagnoses and for all deaths to be used by all investigators conducting research with the NHS data.
Core B activities are critical for confirming disease reports and deaths in the Nurses'Health Study and hence for allowing valid analyses to be conducted in Projects 1-4. By extension, this Core is vital to our ability to find ways to prevent cancer incidence and improve survival in women.
|Li, W-Q; Han, J; Cho, E et al. (2016) Personal history of psoriasis and risk of incident cancer among women: a population-based cohort study. Br J Dermatol 174:1108-11|
|Sisti, Julia S; Collins, Laura C; Beck, Andrew H et al. (2016) Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the nurses' health studies. Int J Cancer 138:2346-56|
|Yuan, Chen; Clish, Clary B; Wu, Chen et al. (2016) Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. J Natl Cancer Inst 108:djv409|
|Poole, Elizabeth M; Kubzansky, Laura D; Sood, Anil K et al. (2016) A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients. Cancer Causes Control 27:661-8|
|Mima, Kosuke; Nishihara, Reiko; Nowak, Jonathan A et al. (2016) MicroRNA MIR21 and T Cells in Colorectal Cancer. Cancer Immunol Res 4:33-40|
|Carreras-Torres, Robert; Haycock, Philip C; Relton, Caroline L et al. (2016) The causal relevance of body mass index in different histological types of lung cancer: A Mendelian randomization study. Sci Rep 6:31121|
|Song, Mingyang; Giovannucci, Edward (2016) Preventable Incidence and Mortality of Carcinoma Associated With Lifestyle Factors Among White Adults in the United States. JAMA Oncol 2:1154-61|
|Yang, M; Hu, F B; Giovannucci, E L et al. (2016) Nut consumption and risk of colorectal cancer in women. Eur J Clin Nutr 70:333-7|
|Earp, Madalene; Winham, Stacey J; Larson, Nicholas et al. (2016) A targeted genetic association study of epithelial ovarian cancer susceptibility. Oncotarget 7:7381-9|
|Garcia-Albeniz, Xabier; Rudolph, Anja; Hutter, Carolyn et al. (2016) CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk. Br J Cancer 114:221-9|
Showing the most recent 10 out of 1498 publications